Mono-chemotherapy of a selective EZH2 inhibitor such as GSK126, or combination chemotherapy using a selective EZH2 inhibitor and one or more conventional anticancer drugs, might be an appropriate strategy to cure high-risk endometrial cancer. The gene discussed is EZH2; the disease is endometrial cancer.